A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients with Recurrent High-Grade Glioma
Clinical Trial Grant
Awarded By
ImmVira Pharma Co., Ltd.
Start Date
May 9, 2023
End Date
September 30, 2026
Awarded By
ImmVira Pharma Co., Ltd.
Start Date
May 9, 2023
End Date
September 30, 2026